Additional file 9 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Authors :: Romito, Ilaria
Porru, Manuela
Braghini, Maria Rita
Pompili, Luca
Panera, Nadia
Crudele, Annalisa
Gnani, Daniela
De Stefanis, Cristiano
Scarsella, Marco
Pomella, Silvia
Levi Mortera, Stefano
de Billy, Emmanuel
Conti, Adrian Libenzio
Marzano, Valeria
Putignani, Lorenza
Vinciguerra, Manlio
Balsano, Clara
Pastore, Anna
Rota, Rossella
Tartaglia, Marco
Leonetti, Carlo
Alisi, Anna
Publication Year :: 2021
Publisher :: figshare, 2021.
Abstract: Additional file 9: Figure S4. Pilot study for quantitative setting of TAE226 concentration in a heterotopic HepG2 xenograft model of HCC. (A) Quantitative analysis of tumour weight at various time points in NT animals or after TAE226 treatments. P values were calculated at day 12 using an unpaired two-tailed t-test, between treated and untreated tumours. **** p

Full Text Access

Tools